Article Information
History
- April 6, 2024.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Author Information
- Shona M. Kerr1,
- Lucija Klaric1,
- Marisa D. Muckian2,3,
- Emma Cowan4,
- Lesley Snadden4,
- Gannie Tzoneva5,
- Alan R. Shuldiner5,
- Zosia Miedzybrodzka4,6 and
- James F. Wilson1,2,7,†
- 1MRC Human Genetics Unit, University of Edinburgh, Institute of Genetics and Cancer, Western General Hospital, Crewe Road, Edinburgh, EH4 2XU, UK
- 2Centre for Global Health Research, Usher Institute, University of Edinburgh, Teviot Place, Edinburgh EH8 9AG, UK
- 3Department of Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine, Keppel Street, London WC1E 7HT, UK
- 4Department of Medical Genetics, Ashgrove House, NHS Grampian, Aberdeen, AB25 2ZA, UK
- 5Regeneron Genetics Center, Tarrytown, NY, USA
- 6Medical Genetics Group, University of Aberdeen, Polwarth Building, Aberdeen, AB25 2ZD, UK
- 7Centre for Genomic and Experimental Medicine, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, EH4 2XU, UK
- ↵†To whom correspondence should be addressed: jim.wilson{at}ed.ac.uk
Posted April 06, 2024.
Two founder variants account for over 90% of pathogenic BRCA alleles in Orkney and Shetland
